Ahorro del sistema de salud por la regulación directa de precios de venta de medicamentos biotecnológicos en Colombia

We developed a retrospective analysis on the sales of thirteen biotechnological regulated medi-cines between June, 2010, and June, 2014, in two scenarios: Amounts billed after the price and assumed value regulation, calculated based on the average sale price during the six months prior to the regula...

Full description

Autores:

Sánchez-Villalobos O.
Mesa-Escobar G.H.
Ruíz-Correa A.F.
Quintero Ortiz, Diego Nadin
López S.L.
Serna-Guerrero J.S.
Muñoz-Díaz P.A.

Tipo de recurso:

Article of journal

Fecha de publicación:

2016

Institución:

Universidad Cooperativa de Colombia

Repositorio:

Repositorio UCC

Idioma:

OAI Identifier:

oai:repository.ucc.edu.co:20.500.12494/41776

Acceso en línea:

https://doi.org/10.1590/2175-35392018039914
http://ojs.urepublicana.edu.co/index.php/pensamientorepublicano/article/view/423/389
https://hdl.handle.net/20.500.12494/41776

Palabra clave:

Biotechnology
Cost control
Economic analysis
Health economy
Medical savings
Product marketing

Rights

closedAccess

License

http://purl.org/coar/access_right/c_14cb